Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brunswick Corporation (BC) vs Cassava Sciences Inc (FLNA) Price & Performance

Brunswick CorporationTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Brunswick Corporation vs Cassava Sciences Inc — how do they compare? Brunswick Corporation trades at $81.99 (market cap $5.28B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Brunswick Corporation is far larger — about 110.6× Cassava Sciences Inc's market cap, and Brunswick Corporation pays a 2.16% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

BCFLNA
Market Cap
$5.28B$47.75M
Sector
Consumer CyclicalHealth
52-Week High
$89.22$4.64
52-Week Low
$58.75$0.87
Enterprise Value
$7.28B-$34.93M
Dividend Yield
2.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brunswick Corporation

No Aura AI signal available yet.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

About Brunswick Corporation

Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines

Read more on BC

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA